Cargando…

Development, Implementation, and Use of a Neurology Therapeutics Committee

Innovative therapeutics are transforming care of children with previously untreatable neurological disorders. However, there are challenges in the use of new therapies: the medicine may not be effective in all patients, administration may not be tolerated, and matching therapy choice to patient is c...

Descripción completa

Detalles Bibliográficos
Autores principales: Clark, Edward B., Butterfield, Russell J., Filloux, Francis M., Bonkowsky, Joshua L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378459/
https://www.ncbi.nlm.nih.gov/pubmed/30800699
http://dx.doi.org/10.1177/2329048X19830473
_version_ 1783395934361616384
author Clark, Edward B.
Butterfield, Russell J.
Filloux, Francis M.
Bonkowsky, Joshua L.
author_facet Clark, Edward B.
Butterfield, Russell J.
Filloux, Francis M.
Bonkowsky, Joshua L.
author_sort Clark, Edward B.
collection PubMed
description Innovative therapeutics are transforming care of children with previously untreatable neurological disorders. However, there are challenges in the use of new therapies: the medicine may not be effective in all patients, administration may not be tolerated, and matching therapy choice to patient is complex. Finally, costs are high, which imposes financial burdens on insurance companies, families, and the health-care system. Our objective was to address challenges for clinical implementation of the new therapeutics. We sought to develop a process that would be personalized for patient and disease, encourage appropriate use of a therapeutic agent while mitigating pressure on a clinician to prescribe the therapy in all instances, and assist third-party payers in approving therapeutic use based on safety and efficacy. We report our creation of a Neurology Therapeutics Committee for pediatric patients. We review the committee’s mechanisms, describe its use and report outcomes, and suggest the Neurology Therapeutics Committee’s broader applicability.
format Online
Article
Text
id pubmed-6378459
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-63784592019-02-22 Development, Implementation, and Use of a Neurology Therapeutics Committee Clark, Edward B. Butterfield, Russell J. Filloux, Francis M. Bonkowsky, Joshua L. Child Neurol Open Brief Communication Innovative therapeutics are transforming care of children with previously untreatable neurological disorders. However, there are challenges in the use of new therapies: the medicine may not be effective in all patients, administration may not be tolerated, and matching therapy choice to patient is complex. Finally, costs are high, which imposes financial burdens on insurance companies, families, and the health-care system. Our objective was to address challenges for clinical implementation of the new therapeutics. We sought to develop a process that would be personalized for patient and disease, encourage appropriate use of a therapeutic agent while mitigating pressure on a clinician to prescribe the therapy in all instances, and assist third-party payers in approving therapeutic use based on safety and efficacy. We report our creation of a Neurology Therapeutics Committee for pediatric patients. We review the committee’s mechanisms, describe its use and report outcomes, and suggest the Neurology Therapeutics Committee’s broader applicability. SAGE Publications 2019-02-14 /pmc/articles/PMC6378459/ /pubmed/30800699 http://dx.doi.org/10.1177/2329048X19830473 Text en © The Author(s) 2019 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Brief Communication
Clark, Edward B.
Butterfield, Russell J.
Filloux, Francis M.
Bonkowsky, Joshua L.
Development, Implementation, and Use of a Neurology Therapeutics Committee
title Development, Implementation, and Use of a Neurology Therapeutics Committee
title_full Development, Implementation, and Use of a Neurology Therapeutics Committee
title_fullStr Development, Implementation, and Use of a Neurology Therapeutics Committee
title_full_unstemmed Development, Implementation, and Use of a Neurology Therapeutics Committee
title_short Development, Implementation, and Use of a Neurology Therapeutics Committee
title_sort development, implementation, and use of a neurology therapeutics committee
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378459/
https://www.ncbi.nlm.nih.gov/pubmed/30800699
http://dx.doi.org/10.1177/2329048X19830473
work_keys_str_mv AT clarkedwardb developmentimplementationanduseofaneurologytherapeuticscommittee
AT butterfieldrussellj developmentimplementationanduseofaneurologytherapeuticscommittee
AT fillouxfrancism developmentimplementationanduseofaneurologytherapeuticscommittee
AT bonkowskyjoshual developmentimplementationanduseofaneurologytherapeuticscommittee